News stories about Ligand Pharmaceuticals (NASDAQ:LGND) have been trending somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.5998834890625 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Ligand Pharmaceuticals (LGND) traded down $2.51 during mid-day trading on Tuesday, hitting $146.39. 188,315 shares of the stock were exchanged, compared to its average volume of 211,710. Ligand Pharmaceuticals has a twelve month low of $95.08 and a twelve month high of $151.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.97 and a quick ratio of 0.95. The firm has a market capitalization of $3,130.00, a P/E ratio of 212.16, a P/E/G ratio of 1.59 and a beta of 0.91.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.32. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The business had revenue of $33.38 million during the quarter, compared to the consensus estimate of $31.04 million. During the same quarter last year, the company earned $0.62 earnings per share. The business’s quarterly revenue was up 54.4% compared to the same quarter last year. research analysts forecast that Ligand Pharmaceuticals will post 3.15 EPS for the current fiscal year.

A number of research firms have recently weighed in on LGND. HC Wainwright reissued a “buy” rating and set a $157.00 price target on shares of Ligand Pharmaceuticals in a research report on Thursday, October 5th. Craig Hallum reissued a “buy” rating and set a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Finally, Roth Capital set a $158.00 price target on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $150.67.

In other Ligand Pharmaceuticals news, VP Matthew E. Korenberg sold 6,559 shares of Ligand Pharmaceuticals stock in a transaction on Friday, November 17th. The shares were sold at an average price of $142.63, for a total value of $935,510.17. Following the completion of the transaction, the vice president now owns 8,147 shares of the company’s stock, valued at $1,162,006.61. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John W. Kozarich sold 2,500 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the completion of the transaction, the director now directly owns 33,149 shares of the company’s stock, valued at approximately $4,806,605. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,253 shares of company stock valued at $2,884,507. 8.30% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/16/ligand-pharmaceuticals-lgnd-given-daily-media-sentiment-score-of-0-14.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Stock Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related stocks with our FREE daily email newsletter.